Integrated Filing — IndAS



General information about company

Scrip Code 540937
NSE Symbol MEDICO
MSEI Symbol NOTLISTED
ISIN INE630Y01024
Name of company MEDICO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 21-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment manufacturer and exporter of pharmaceutical formulations
Start date and time of board meeting 21-05-2026   17:00:00
End date and time of board meeting 21-05-2026   17:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 05-02-2025
Indicate Company website link for updated RPT policy of the Company https://medicoremedies.com/soon.html
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,680.77 20,637.73
Other income 287.39 593.35
Total income 5,968.16 21,231.08
2 Expenses
(a) Cost of materials consumed 4,034.43 14,858.71
(b) Purchases of stock-in-trade 45.59 441.32
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (136.39) (167.27)
(d) Employee benefit expense 175.54 739.82
(e) Finance costs 90.38 180.63
(f) Depreciation, depletion and amortisation expense 80.19 309.46
(f) Other Expenses
1 Manufacturing, Selling and other Business Expenses 846.49 3,062.45
Total other expenses 846.49 3,062.45
Total expenses 5,136.23 19,425.12
3 Total profit before exceptional items and tax 831.93 1,805.96
4 Exceptional items 0.00 0.00
5 Total profit before tax 831.93 1,805.96
6 Tax expense
7 Current tax 288.55 505.55
8 Deferred tax (42.29) (11.11)
9 Total tax expenses 246.26 494.44
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 585.67 1,311.52
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 585.67 1,311.52
17 Other comprehensive income net of taxes (11.32) (10.96)
18 Total Comprehensive Income for the period 574.35 1,300.56
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,659.68 1,659.68
Face value of equity share capital 2 5887.77
27 Details of debt securities
22 Reserves excluding revaluation reserve 5,887.77
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.71 1.58
Diluted earnings (loss) per share from continuing operations 0.71 1.58
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.71 1.58
Diluted earnings (loss) per share from continuing and discontinued operations 0.71 1.58
24 Debt equity ratio 0.2500 0.2500
25 Debt service coverage ratio 11.0900 11.1600
26 Interest service coverage ratio 10.200 19.2200
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1.The above audited standalone financial results of the company were reviewed and recommended by the audit committee on May 21, 2026 and subsequently approved by the Board of Directors at its meeting held on May 21, 2026. The review report has been filed with stock exchange and is available on the Company’s website. 2.The figures for the quarter ended on 31st March 2026 are balancing figures between the audited figures for the year ended 31st March 2026 and reviewed year to date figures up to nine month ended 31st December 2025. 3.The standalone financial results for the quarter ended on 31st March, 2026 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. 4.The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. 5.Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: PARTICULARS QE 31.03.2026 QE 31.12.2025 Amount (Rs. In Lakh) Amount (Rs. In Lakh) 1)Sales of products within India 274.48 689.73 2)Sales of products Outside India 5364.29 5156.03 Sub- Total 5638.77 5845.76 6.Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. 7.The company does not have any subsidiary/associate/joint venture company as on 31st March 2026. 8.The result for the quarter ended March 31, 2026 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) For and on behalf of the board, For Medico Remedies Limited Haresh Mehta Harshit Mehta Chairman and Whole Time Director Managing Director DIN:01080289 DIN:05144280 Place: Mumbai Place: Mumbai Date: May 21, 2026 Date: May 21, 2026



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2,009.89
Capital work-in-progress 257.33
Investment property 27.69
Goodwill 0.00
Other intangible assets 3.64
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 4.30
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial asserts 84.06
Total of other non-current financial assets 84.06
Total non-current financial assets 88.36
Deferred tax assets (net) 39.54
Other non-current assets
1 Other non-current assets 22.11
Total of other non-current assets 22.11
Total non-current assets 2,448.56
2 Current assets
Inventories 3,001.58
Current financial asset
Current investments 184.43
Trade receivables, current 8,199.24
Cash and cash equivalents 190.69
Bank balance other than cash and cash equivalents 0.00
Loans, current 28.25
Other current financial assets
Total of other current financial assets 0.52
Total current financial assets 8,603.13
Current tax assets (net)
Other current assets
1 other current assets 1,287.06
Total of other current assets 1,287.06
Total current assets 12,891.77
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 15,340.33
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,659.68
Other equity 5,887.77
Total equity attributable to owners of parent 7,547.45
Non controlling interest
Total equity 7,547.45
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 28.63
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 28.63
Provisions, non-current 0.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 28.63
Current liabilities
Current financial liabilities
Borrowings, current 1,854.90
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 221.40
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4,711.43
Total Trade payable 4,932.83
Other current financial liabilities
1 Lease Liability 36.88
Total of other current financial liabilities 36.88
Total current financial liabilities 6,824.61
Other current liabilities 664.18
1 Other current liabilities 664.18
Total of other current liabilities 664.18
Provisions, current 0.00
Current tax liabilities (Net) 275.46
Deferred government grants, Current
Total current liabilities 7,764.25
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 7,792.88
Total equity and liabilites 15,340.33
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Unaudited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plan (15.13) (14.65)
Total Amount of items that will not be reclassified to profit and loss (15.13) (14.65)
2 Income tax relating to items that will not be reclassified to profit or loss (3.81) (3.69)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (11.32) (10.96)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,805.96
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (328.94)
Adjustments for decrease (increase) in trade receivables, current 0.00
Adjustments for decrease (increase) in trade receivables, non-current (2,514.07)
Adjustments for decrease (increase) in other current assets (4.64)
Adjustments for decrease (increase) in other non-current assets (283.84)
Adjustments for other financial assets, non-current (0.09)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,461.49
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 176.53
Adjustments for increase (decrease) in other non-current liabilities 471.66
Adjustments for depreciation and amortisation expense 309.46
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (9.66)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 13.49
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (0.82)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 23.43
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (712.98)
Net cash flows from (used in) operations 1,092.98
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 505.55
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 587.43
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 6.50
Purchase of property, plant and equipment 0.00
Proceeds from sales of investment property 0.00
Purchase of investment property 39.37
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 1.43
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 13.49
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (433.28)
Net cash flows from (used in) investing activities (451.23)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 55.00
Dividends paid 0.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (55.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 81.20
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 81.20
Cash and cash equivalents cash flow statement at beginning of period 109.49
Cash and cash equivalents cash flow statement at end of period 190.69





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Shah Shroff & Associates Yes 30-04-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Medico Remedies Limited Haresh K Mehta Director Remuneration 72.00 NA 22.65 49.33 71.98
2 Medico Remedies Limited Haresh K Mehta Director Any other transaction Rent 20.00 NA 7.00 0.00 0.00
3 Medico Remedies Limited Haresh K Mehta Director Any other transaction Reimbursement of expense 5.00 NA 0.30 0.78 1.08
4 Medico Remedies Limited Harshit H Mehta Director Remuneration 72.00 NA 7.04 3.45 10.49
5 Medico Remedies Limited Harshit H Mehta Director Any other transaction Rent 20.00 NA 7.00 0.00 0.00
6 Medico Remedies Limited Harshit H Mehta Director Any other transaction Reimbursement of expense 5.00 NA (1.66) 1.76 0.10
7 Medico Remedies Limited Harshit H Mehta Director Any other transaction Loan accepted/repaid 100.00 NA 70.00 2.00 72.00
8 Medico Remedies Limited Haresh K Mehta Director Any other transaction Loan accepted/repaid 100.00 NA 75.00 0.00 75.00
9 Medico Remedies Limited Rishit H Mehta Director Remuneration 60.00 NA 17.90 15.52 33.42
10 Medico Remedies Limited Rishit H Mehta Director Any other transaction Rent 10.00 NA 7.00 0.00 0.00
11 Medico Remedies Limited Rishit H Mehta Director Any other transaction Reimbursement of expense 5.00 NA 0.29 0.12 0.41
12 Medico Remedies Limited Rishit H Mehta Director Any other transaction Loan accepted/repaid 100.00 NA 29.00 0.00 29.00
13 Medico Remedies Limited Rita H Mehta Director Any other transaction Rent 20.00 NA 7.00 0.00 0.00
14 Medico Remedies Limited Shweta H Mehta Wife of Director Remuneration 40.00 NA (8.97) 18.64 9.67
15 Medico Remedies Limited Priyal R Mehta Wife of Director Any other transaction Professional Fees paid 24.00 NA 10.80 7.20 18.00
16 Medico Remedies Limited Kapurlal Tribhuvandas Mehta Charitable Trust Trust of Director Any other transaction CSR Contribution 20.00 NA 17.00 5.84 22.84
17 Medico Remedies Limited Maheshkumar Darji Director Remuneration 24.00 NA 11.94 0.00 0.00
Total value of transaction during the reporting period 279.29